SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sleepman who wrote (199)7/8/1997 4:58:00 PM
From: Rick Strange   of 10280
 
Dan,
Levalbuterol, at the 0.625 mg dose, proved to be as effective in raising the forced expiratory volume (FEV) as the standard 2.5mg dose of albuterol, with 50% fewer side effects. Lung function in patients receiving Levalbuterol remained stable and by the fourth study week was significantly better than the lung function in albuterol patients (p<0.05) which tended to deteriorate over time.
Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News